Healthcare provider profile · identity verified

Jennifer E Stull, MD

Family Practice · FINDLAY, OH · NPI 1346569522

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	729	190
Lisinopril	Lisinopril	521	134
Amlodipine Besylate	Amlodipine Besylate	434	130
Levothyroxine Sodium	Levothyroxine Sodium	361	90
Losartan Potassium	Losartan Potassium	304	86
Omeprazole	Omeprazole	255	69
Hydrochlorothiazide	Hydrochlorothiazide	242	71
Rosuvastatin Calcium	Rosuvastatin Calcium	233	64
Gabapentin	Gabapentin	230	57
Pantoprazole Sodium	Pantoprazole Sodium	172	49
Pravastatin Sodium	Pravastatin Sodium	171	42
Metformin Hcl Er	Metformin Hcl	170	44
Metoprolol Succinate	Metoprolol Succinate	160	44
Furosemide	Furosemide	153	41
Metformin Hcl	Metformin Hcl	136	32
Duloxetine Hcl	Duloxetine Hcl	131	33
Fluticasone Propionate	Fluticasone Propionate	129	54
Potassium Chloride	Potassium Chloride	127	36
Simvastatin	Simvastatin	126	29
Alendronate Sodium	Alendronate Sodium	113	40
Trazodone Hcl	Trazodone Hcl	113	30
Montelukast Sodium	Montelukast Sodium	111	28
Jardiance	Empagliflozin	106	25
Famotidine	Famotidine	100	36
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	96	22
Albuterol Sulfate Hfa	Albuterol Sulfate	93	53
Pregabalin	Pregabalin	84	16
Metoprolol Tartrate	Metoprolol Tartrate	79	20
Spironolactone	Spironolactone	78	20
Nifedipine Er	Nifedipine	75	17
Carvedilol	Carvedilol	74	19
Sertraline Hcl	Sertraline Hcl	74	25
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	73	15
Citalopram Hbr	Citalopram Hydrobromide	72	13
Prednisone	Prednisone	72	48
Ezetimibe	Ezetimibe	71	20
Glipizide	Glipizide	67	16
Trulicity	Dulaglutide	67	suppressed
Ipratropium Bromide	Ipratropium Bromide	66	41
Synthroid	Levothyroxine Sodium	66	15
Escitalopram Oxalate	Escitalopram Oxalate	64	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	62	16
Meloxicam	Meloxicam	58	19
Amitriptyline Hcl	Amitriptyline Hcl	57	14
Fenofibrate	Fenofibrate Nanocrystallized	57	13
Zolpidem Tartrate	Zolpidem Tartrate	57	11
Atenolol	Atenolol	55	14
Baclofen	Baclofen	54	suppressed
Breo Ellipta	Fluticasone/Vilanterol	50	12
Clopidogrel	Clopidogrel Bisulfate	49	16
Hydralazine Hcl	Hydralazine Hcl	48	15
Spiriva Respimat	Tiotropium Bromide	48	suppressed
Ozempic	Semaglutide	46	suppressed
Tizanidine Hcl	Tizanidine Hcl	45	25
Tramadol Hcl	Tramadol Hcl	45	15
Eliquis	Apixaban	43	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	43	11
Hydroxyzine Hcl	Hydroxyzine Hcl	43	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	42	13
Lovastatin	Lovastatin	42	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	40	36
Meclizine Hcl	Meclizine Hcl	40	14
Naproxen	Naproxen	40	18
Januvia	Sitagliptin Phosphate	39	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	38	12
Bupropion Xl	Bupropion Hcl	36	13
Mirtazapine	Mirtazapine	35	11
Oxybutynin Chloride Er	Oxybutynin Chloride	35	11
Glipizide Er	Glipizide	34	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	34	11
Valacyclovir	Valacyclovir Hcl	34	11
Valsartan	Valsartan	34	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	32	suppressed
Mounjaro	Tirzepatide	32	suppressed
Diclofenac Sodium	Diclofenac Sodium	31	16
Tamsulosin Hcl	Tamsulosin Hcl	31	11
Rybelsus	Semaglutide	30	suppressed
Trospium Chloride	Trospium Chloride	30	suppressed
Buspirone Hcl	Buspirone Hcl	29	suppressed
Methylprednisolone	Methylprednisolone	29	28
Zolpidem Tartrate Er	Zolpidem Tartrate	28	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	27	suppressed
Cephalexin	Cephalexin	27	26
Donepezil Hcl	Donepezil Hcl	27	suppressed
Azithromycin	Azithromycin	26	24
Memantine Hcl	Memantine Hcl	26	suppressed
Ondansetron Hcl	Ondansetron Hcl	25	11
Alprazolam	Alprazolam	24	suppressed
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	23	suppressed
Azelastine Hcl	Azelastine Hcl	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Allopurinol	Allopurinol	21	suppressed
Lansoprazole	Lansoprazole	21	suppressed
Loperamide	Loperamide Hcl	21	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	21	19
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	20	suppressed
Glimepiride	Glimepiride	20	suppressed
Ibuprofen	Ibuprofen	20	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	19	suppressed
Ondansetron Odt	Ondansetron	19	11
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Klor-Con M20	Potassium Chloride	17	suppressed
Nystatin	Nystatin	17	12
Symbicort	Budesonide/Formoterol Fumarate	17	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	14
Terazosin Hcl	Terazosin Hcl	14	suppressed
Fenofibrate	Fenofibrate,micronized	13	suppressed
Primidone	Primidone	13	suppressed
Colchicine	Colchicine	12	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Spiriva Handihaler	Tiotropium Bromide	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Nyamyc	Nystatin	11	suppressed
Verapamil Sr	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error